EN DE
Watch NatureCell Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NatureCell Co.Ltd (007390) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of NatureCell Co.Ltd stock KRW 10,696, price KRW 20,550, that is 48.0% below the price, quality 39 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7007390008

NC NatureCell Co.Ltd logo Thin data Nov 10, 2026

NatureCell Co.Ltd

007390 · KQ
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +4.4 %/yr in KRW)
Revenue last quarter 9% below a year ago.
Fair value 10,696 KRW · Strongly overvalued
Quality 39/100
Loss-making · -14.9% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch NatureCell Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

40,950 KRW 6,950 KRW Fair Value 10,696 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 6,950 KRW – 40,950 KRW · fair‑value band 8,022 KRW – 13,370 KRW · the 20,550 KRW price screens above the 10,696 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow NatureCell Co.Ltd in your weekly email

Every Wednesday you see whether NatureCell Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NatureCell Co.,Ltd. manufactures and sells canned and health functional food products, beverages, stem cell, and cosmetics in South Korea and internationally.

Show moreShow less

The company's products comprise fruit drinks, aloe vera drinks, coffee, energy drinks, and Korean sauces, as well as offers domestic products and ETC products under the SAMMI and OEM brands.

It also provides services for the preservation of blood cells, such as endothelial progenitor cells, mononuclear cells, and platelet rich plasma products. The company was formerly known as RNL Sammi CO., Ltd. and changed its name to NatureCell Co.,Ltd. in April 2013.

NatureCell Co.,Ltd. was founded in 1960 and is based in Seoul, South Korea.

Stock analysis

NatureCell Co.Ltd (007390) currently trades at 20,550 KRW, while our estimate is 10,696 KRW, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 8,022 KRW (bear) to 13,370 KRW (bull), the price of 20,550 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

NatureCell Co.Ltd reported revenue of 20.7B KRW in FY2025 versus 22.2B KRW in FY2021, a compound −1.7%/yr. Reported net income was −2.8B KRW in FY2025.

Key figures

Market cap 1.3T KRW (≈ $993M) Small · P/S ratio 51.1 · Net margin −14.9% · Return on equity −28.8% · Return on assets (EBIT) −9.6% (5-year average) · Operating margin 0.2% · Revenue (TTM) 27.9B KRW · Revenue growth (YoY) −9.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −48%, 007390 screens richer than that median.

Fair Value

Bear 8,022 KRW Fair Value 10,696 KRW Bull 13,370 KRW
Price 20,550 KRW · Downside -48.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 93
Debt, balance sheet and risk of trouble
Investment 61
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 38
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 76
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 1/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−35.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Start year 2020 (pandemic). Over 10 years: −3.8% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.0% (2020) → −17.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

007390 screens overvalued: fair value 48% below the price. Compare with ST Pharm Co →

Compare NatureCell Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −48.0% · Below median
Profitability
Return on assets −3.8% · Bottom 25%
Net margin (12 months) −14.9% · Bottom 25%
Operating margin (12 months) 0.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) −9.0% · Bottom 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 21.01× · Priciest 25%
P/S (12 months) 47.50× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 6
FUTURE (revenue growth)0 · sector 51
PAST (return on equity)0 · sector 10
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,750 KRW 47,019 KRW +138% vs 007390
DongKook Pharmaceutical Co 086450 24,750 KRW 28,372 KRW +15% vs 007390
VIKRAMTH VIKRAMTH ₹324.45 ₹356.90 +10% vs 007390
ST Pharm Co 237690 75,500 KRW 61,182 KRW −19% vs 007390
Vivozon Pharmaceutical Co 082800 3,000 KRW 2,150 KRW −28% vs 007390
Oscotec Inc 039200 36,050 KRW 21,262 KRW −41% vs 007390
Mezzion Pharma Co 140410 65,600 KRW 31,450 KRW −52% vs 007390
BINEX Co 053030 6,330 KRW 1,844 KRW −71% vs 007390
Caregen Co 214370 27,000 KRW 5,414 KRW −80% vs 007390
SHUKRAPHAR SHUKRAPHAR ₹82.11 ₹9.14 −89% vs 007390

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NatureCell Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NatureCell Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/007390

Frequently asked questions

Is NatureCell Co.Ltd (007390) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 10,696 KRW versus a price of 20,550 KRW, about 48% lower (overvalued).
What is the fair value of 007390?
Our estimate for NatureCell Co.Ltd is 10,696 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 20,550 KRW.
What is the quality score of 007390?
NatureCell Co.Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NatureCell Co.Ltd (007390)?
Our calculated price target is the estimate of 10,696 KRW (as of Nov 10, 2026). Cautious scenario 8,022 KRW, optimistic scenario 13,370 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NatureCell Co.Ltd stock forecast for 2026?
Our estimate puts fair value at 10,696 KRW, about 48% lower versus a price of 20,550 KRW (overvalued). Cautious scenario 8,022 KRW, optimistic scenario 13,370 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of NatureCell Co.Ltd (007390)?
NatureCell Co.Ltd reported trailing-twelve-month revenue of about 27.9B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of NatureCell Co.Ltd (007390)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NatureCell Co.Ltd it is 10,696 KRW per share (as of Nov 10, 2026), against a price of 20,550 KRW.
Is NatureCell Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 007390 trades above its calculated fair value: price 20,550 KRW, fair value 10,696 KRW, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 007390?
No. The price is what the market pays today (20,550 KRW); the fair value is what the company's own numbers justify (10,696 KRW). For NatureCell Co.Ltd the two are 9,854 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is NatureCell Co.Ltd worth?
The market values NatureCell Co.Ltd at about 1.3T KRW (market capitalisation, as of Nov 10, 2026). Per share that is 20,550 KRW; our models calculate a fair value of 10,696 KRW per share.
What do the bullish and bearish scenarios say about 007390?
Our models span a range for NatureCell Co.Ltd: cautious scenario 8,022 KRW, base 10,696 KRW, optimistic 13,370 KRW per share (as of Nov 10, 2026, price 20,550 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NatureCell Co.Ltd (007390)?
Balance-sheet figures for NatureCell Co.Ltd (as of Nov 10, 2026): return on equity −28.8%. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 007390 from its 52-week high?
NatureCell Co.Ltd trades at 20,550 KRW, about 41% below its 52-week high of 34,550 KRW and 22% above the low of 16,900 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 10,696 KRW is for.
Which stocks are comparable to NatureCell Co.Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, Oscotec Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NatureCell Co.Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 20,550 KRW, calculated fair value 10,696 KRW (−48%), Quality Score 39/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. NatureCell Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NatureCell Co.Ltd (007390)?
The closing price on Nov 10, 2026 was 20,550 KRW. Our estimate is 10,696 KRW, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NatureCell Co.Ltd right now?
The price sits above even our optimistic bull case (13,370 KRW). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of NatureCell Co.Ltd

How large is the market capitalisation of NatureCell Co.Ltd (007390)?
The market capitalisation of NatureCell Co.Ltd is 1.3T KRW (≈ $993M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NatureCell Co.Ltd (007390)?
The price-to-sales ratio of NatureCell Co.Ltd is 51.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of NatureCell Co.Ltd (007390)?
The net margin of NatureCell Co.Ltd is −14.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NatureCell Co.Ltd (007390)?
The return on equity (ROE) of NatureCell Co.Ltd is −28.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NatureCell Co.Ltd (007390)?
On an EBIT basis the return on assets of NatureCell Co.Ltd is −9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NatureCell Co.Ltd (007390)?
The operating margin of NatureCell Co.Ltd is 0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NatureCell Co.Ltd (007390)?
Revenue at NatureCell Co.Ltd is growing −9.0% versus a year earlier (3y avg −0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NatureCell Co.Ltd (007390) generate?
The free cash flow of NatureCell Co.Ltd is −16.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch NatureCell Co.Ltd in the live analysis

One click puts NatureCell Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.